S&P Futures
4,123.50 -1.00 (-0.02%) Dow Futures
32,740.00 +3.00 (+0.01%) Nasdaq Futures
13,021.00 -10.50 (-0.08%) Russell 2000 Futures
1,913.00 -1.60 (-0.08%) Crude Oil
90.17 -0.33 (-0.36%) Gold
1,809.70 -2.60 (-0.14%)
Achieve Life Sciences, Inc. (ACHV)
Chart Events
Performance Outlook
| Previous Close | 4.9900 |
| Open | 4.9500 |
| Bid | 4.5000 x 800 |
| Ask | 5.0500 x 1800 |
| Day's Range | 4.9500 - 5.0550 |
| 52 Week Range | 4.8100 - 10.0900 |
| Volume | |
| Avg. Volume | 28,970 |
| Market Cap | 47.925M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6560 |
| Earnings Date | Aug 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ACHV
Related Research
- Achieve Life Sciences, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat2 days agoMorningstar
- GlobeNewswire
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT. To access the webcast, please use the
- GlobeNewswire
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors approved the new employment inducement grants to purchase an aggregate of 15,000 shares of Ach
- GlobeNewswire
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily compared to placebo in approximately 150 a
